Jump to main content
Jump to site search

Issue 7, 2011
Previous Article Next Article

FDA-approved poly(ethylene glycol)–protein conjugate drugs

Author affiliations

Abstract

PEGylation or covalent attachment of poly(ethylene glycol) improves the pharmacokinetic properties of protein drugs. In vivo circulation lifetimes are increased and dosages are decreased, resulting in improved patient quality of life. PEG may be attached to proteins using a variety of different chemical reactions. This review discusses currently available FDA-approved PEGylated protein drugs, their intended use and target, and the PEG attachment chemistry utilized.

Graphical abstract: FDA-approved poly(ethylene glycol)–protein conjugate drugs

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 21 Jan 2011, accepted on 20 Mar 2011 and first published on 27 Apr 2011


Article type: Review Article
DOI: 10.1039/C1PY00034A
Citation: Polym. Chem., 2011,2, 1442-1448
  •   Request permissions

    FDA-approved poly(ethylene glycol)–protein conjugate drugs

    S. N. S. Alconcel, A. S. Baas and H. D. Maynard, Polym. Chem., 2011, 2, 1442
    DOI: 10.1039/C1PY00034A

Search articles by author